AEVANOVA NEWSAEVANOVA VESTI

Signal,
not noise.Signal,
bez šuma.

Material developments in peptide regulation, human research, clinical trials and analytical testing—reported from primary sources and separated from the evidence library.Važni događaji u regulativi peptida, istraživanjima na ljudima, kliničkim studijama i analitičkom testiranju—prikazani iz primarnih izvora i odvojeni od biblioteke dokaza.

RegulatoryRegulatornoResearchIstraživanjaClinical TrialsKlinička ispitivanjaSafety & VerificationBezbednost i verifikacijaIndustryIndustrijaAEVANOVA TestingAEVANOVA testiranje
Last reviewed 24 October 2026Poslednji pregled 24. oktobar 2026.
ResearchIstraživanja
Peer-reviewed signal detection — not incidenceRecenzirano otkrivanje signala — nije učestalost

What social-media reports reveal about nonapproved retatrutide—and what they cannot proveŠta objave na društvenim mrežama otkrivaju o neodobrenom retatrutidu—i šta ne mogu dokazati

A JAMA Network Open study mapped self-reported symptoms from online users of products described as retatrutide. It is a meaningful surveillance signal, but neither product identity nor causality could be verified.Studija u časopisu JAMA Network Open mapirala je simptome koje su onlajn korisnici proizvoda opisanih kao retatrutid sami prijavili. To je značajan signal praćenja, ali ni identitet proizvoda ni uzročnost nisu mogli biti potvrđeni.

Read the source-led briefPročitaj pregled zasnovan na izvorima
Clinical TrialsKlinička ispitivanja
Phase III dataset · exploratory post-hoc analysesPodaci faze III · eksplorativne post-hoc analize

CagriSema reached 25% mean weight loss in women—but the subgroup question remains openCagriSema je kod žena dostigla prosečno smanjenje mase od 25%—ali pitanje podgrupa ostaje otvoreno

Novo Nordisk reported REDEFINE 1 analyses in women overall and across inferred menopause stages. The magnitude is notable; the analyses do not prove a female- or menopause-specific treatment advantage.Novo Nordisk je objavio analize REDEFINE 1 kod žena ukupno i kroz izvedene stadijume menopauze. Veličina efekta je značajna, ali analize ne dokazuju posebnu prednost terapije kod žena ili u menopauzi.

Open briefOtvori pregled
Safety & VerificationBezbednost i verifikacija
FDA Class II recall · ongoingFDA opoziv klase II · u toku

Compounded tirzepatide and NAD+ recalled over lack of sterility assuranceKomponovani tirzepatid i NAD+ povučeni zbog nedovoljne potvrde sterilnosti

The FDA enforcement record covers 22 tirzepatide vials and one NAD+ vial from Apothecary Pharma. The record identifies a sterility-assurance failure—not confirmed contamination.Zapis FDA obuhvata 22 bočice tirzepatida i jednu bočicu NAD+ kompanije Apothecary Pharma. Zapis navodi nedovoljnu potvrdu sterilnosti—a ne potvrđenu kontaminaciju.

Open briefOtvori pregled
RegulatoryRegulatorno
Advisory review — not approvalSavetodavno razmatranje — nije odobrenje

FDA advisory committee reviews seven peptide-related substances for the 503A Bulks ListSavetodavni odbor FDA razmatrao sedam supstanci povezanih sa peptidima za 503A listu

BPC-157, KPV, TB-500 and MOTS-c were among the bulk drug substances discussed. The meeting was a 503A compounding-list review—not FDA approval of these substances as medicines.BPC-157, KPV, TB-500 i MOTS-c bili su među razmatranim aktivnim supstancama. Sastanak je bio procena za 503A listu za izradu lekova, a ne odobrenje FDA za ove supstance kao lekove.

Open briefOtvori pregled
Clinical TrialsKlinička ispitivanja
Company topline disclosurePreliminarno saopštenje kompanije

Lilly discloses Phase III topline results from TRIUMPH-2 and TRIUMPH-3Lilly objavio preliminarne rezultate faze III iz TRIUMPH-2 i TRIUMPH-3

The two placebo-controlled studies add late-stage evidence in defined obesity populations, but detailed peer-reviewed reports were still pending at the time of disclosure.Dve placebom kontrolisane studije dodaju kasne kliničke dokaze u definisanim populacijama sa gojaznošću, ali su detaljni recenzirani izveštaji u trenutku objave još bili na čekanju.

Open briefOtvori pregled
ResearchIstraživanja
Peer-reviewed Phase III evidenceRecenzirani dokazi faze III

First peer-reviewed Phase III retatrutide trial publishedObjavljena prva recenzirana studija faze III retatrutida

TRANSCEND-T2D-1 studied retatrutide monotherapy in 537 adults with type 2 diabetes inadequately controlled by diet and exercise.TRANSCEND-T2D-1 je proučavao monoterapiju retatrutidom kod 537 odraslih sa dijabetesom tipa 2 koji nije bio adekvatno kontrolisan ishranom i fizičkom aktivnošću.

Open briefOtvori pregled
Editorial firewallUrednička granica

News is not a clinical claim.Vest nije klinička tvrdnja.

A regulatory meeting, trial announcement, lawsuit or investment can be important without changing the established evidence for a compound. Every brief labels the source type and unresolved questions.Regulatorni sastanak, najava studije, sudski postupak ili investicija mogu biti važni bez promene utvrđenih dokaza za jedinjenje. Svaki pregled označava vrstu izvora i nerešena pitanja.